illumicell AI, a Boston, MA-based techmed startup, raised $2M in pre-seed funding.
Traders included healthcare operators, clinicians, and early-stage funds reminiscent of KOFA Healthcare, Harvard Phoenix Enterprise Fund, and MedTechSyndicates, in addition to Dr. Jeremy Teoh.
The corporate intends to make use of the funds to speed up growth of its options.
Based by Harvard-trained doctor Michel Bielecki, former McKinsey guide Jeyla Sadikova, and rocket engineer Loup Cordey, illumicell AI is advancing a conveyable “lab scanner” and a real-time AI platform for fluid-based diagnostics, able to analyzing cells and biomarkers inside minutes.
Every scan generates structured, labeled cell knowledge, unlocking personalised insights like lifestyle-linked fertility adjustments, complement responses, and early fertility decline warnings. Whereas at the moment centered on semen, the platform has broader purposes throughout fluids like urine and cerebrospinal fluid. As early scientific trials already outperform legacy techniques, FDA submission is deliberate for 2026.
illumicell AI has been chosen by innovation applications together with Harvard i-Labs, Artistic Destruction Lab, MassChallenge, Techstars, and Keihanna KGAP+.
FinSMEs
10/04/2025
